This funding will support the technology to reach its next major milestone: financing the clinical proof of concept. The goal is to demonstrate that the system functions not only in laboratory settings but also with preterm infants.

Inhale+ aims to revolutionize inhalation therapy for premature babies by introducing a patented, non-invasive approach. This gentle and highly effective treatment option addresses the needs of underdeveloped lungs in preterm infants, enabling the preventive management of respiratory diseases. The innovative bypass technology diverts a small, precisely controlled volume of air from the ventilation circuit, enriches it with a pharmaceutical aerosol, and delivers the highly concentrated aerosol directly to the patient’s airways. This method achieves 3.2 times the efficacy of conventional inhalation therapies.

Together with our partners – Hannover Medical School (MHH) and University Hospital Schleswig-Holstein (UKSH) – we are eager to ensure that the prototypes meet all safety and compliance standards, paving the way for clinical trials. This method represents a significant breakthrough in neonatal care, promising improved treatment quality and outcomes for this vulnerable patient group worldwide.